Prevalence and Predictors of Fatigue in Inflammatory Bowel Disease: A Cross-Sectional Cohort Study With Subgroup Analysis of Quiescent Disease (ACG 2026) - Aug 29, 2026 - Abstract #P1199; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; HBI, Harvey-Bradshaw Index; IFX, infliximab; PSQI, Pittsburgh Sleep Quality Index; RZB, risankizumab; TNF, tumour necrosis factor; TOFA, tofacitinib; UPA, upadacitinib; UST, ustekinumab; VDZ, vedolizumab. A total of 215 patients (71.2% Crohnâs, 42.3% female, median age 30) completed FACIT-F; 201 (93.5%) had classifiable IBD clinical activity (69 active, 132 quiescent) and included in the analysis. Moderate-severe fatigue affected 82 (38.1%) overall; 44.9% in active and 33.3% in quiescent disease (50% in those with elevated biomarkers) (Figure 1A). On univariate analysis, moderate-severe fatigue was associated with HBI (p=0.034), CRP (p=0.03), poor sleep (PSQIâ¥5; p< 0.001), depression (HADS-D â¥8; p< 0.001) and anxiety (HADS-A â¥8; p< 0.001) (Table 1)."
CNS Disorders • Crohn's disease • Depression • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • CRP
|
|
Naif Alrossais MD 1; Abdul Razzak Chalab Cham MBBS 2; Samhar Alouch 2; Haneen Abu Raida MBBS 2; Mohamed Naim Khalil MBBS 2; Abdulelah Almutairdi MD 1; Mashary Attamimi MD 1; Badr Al-Bawardy MBBS 1
|